Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals

Pallavi Madhiraju- June 8, 2024 0

In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals in an all-cash transaction valued at $466 ... Read More

Vanda Pharmaceuticals rejects Future Pak’s acquisition offer

Pallavi Madhiraju- May 26, 2024 0

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has officially declined the latest acquisition proposal from Future Pak, LLC (FP), citing substantial undervaluation and significant risk. The offer, ... Read More

Vanda Pharmaceuticals gets FDA orphan drug status for VPO-227 in cholera

Pallavi Madhiraju- October 22, 2022 0

Vanda Pharmaceuticals has secured orphan drug designation for VPO-227 from the US Food and Drug Administration (FDA) for the treatment of cholera. According to the ... Read More